6
Participants
Start Date
March 21, 2023
Primary Completion Date
September 23, 2024
Study Completion Date
September 23, 2024
CyPep-1
Intratumoral injection
Pembrolizumab 25 MG/ML [KEYTRUDA®]
IV infusion
University of Alabama at Birmingham, Birmingham
Henry Ford Health System, Detroit
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Houston Methodist, Houston
City Of Hope, Duarte
University of Pittsburgh Medical Center, Pittsburgh
CHRU de Besançon, Besançon
Institut Bergonie, Bordeaux
CHU Lille, Lille
Centre Leon Berard, Lyon
AP-HM - Hôpital de la Timone, Marseille
Institut Paoli Calmettes, Marseille
Hôpital Saint Louis - AP-HP, Paris
Institute Gustave Roussy, Villejuif
Istituto Europeo di Oncologia, Milan
Azienda Ospedaliero Universitaria Senese, Siena
NKI/AvL, Amsterdam
Maastricht UMC, Maastricht
EMC, Rotterdam
Vall d'Hebron (VHIO), Barcelona
Clinica Universidad de Navarra Madrid, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario HM Sanchinarro, Madrid
Clinica Universidad de Navarra Pamplona, Pamplona
Hospital Universitario Virgen Macarena, Seville
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Cytovation AS
INDUSTRY